2025年弥合差距会议多发性骨髓瘤管理共识建议
The rapid expansion of therapeutic options for multiple myeloma (MM) has created uncertainty regarding optimal sequencing and clinical application.…
要点
- 共识推荐整合四联诱导方案用于多发性骨髓瘤治疗。
- 维持治疗应个体化,依据患者特征调整。
- CAR-T治疗应早期转诊,避免延误。
研究设计与样本
- 2025年Bridging the Gaps共识会议召集16位美国多发性骨髓瘤专家,采用改良Delphi法对51个问题投票。
主要发现
- 共识覆盖冒烟型骨髓瘤、frontline治疗、移植、维持和复发难治疾病,关键主题包括四联诱导整合、个体化维持和早期CAR-T转诊。
关键数值与推荐
- 推荐条款包括整合四联诱导、个体化维持和早期转诊CAR-T治疗。
临床怎么用
- 临床可参考共识建议优化多发性骨髓瘤治疗顺序,注重四联诱导和个体化维持,并早期评估CAR-T治疗指征。
局限性
- 共识基于专家意见,部分领域证据不足,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rapid expansion of therapeutic options for multiple myeloma (MM) has created uncertainty regarding optimal sequencing and clinical application. To address gaps in evidence, the 2025 Bridging the Gaps Consensus Conference convened 16 US MM experts who reviewed data, debated controversies, and voted on 51 questions that were developed using a modified Delphi approach. Eleven consensus recommendations were developed spanning smoldering MM, frontline therapy, transplant, maintenance, and relapsed/refractory disease. Key themes included integration of quadruplet induction, individualized maintenance, and early referral for CAR-T therapy. These expert-derived recommendations provide practical guidance while highlighting areas requiring further investigation.
引用
- Chari A, Costello C, Krishnan A, et al. Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference. Am J Hematol. 2026. PMID: 42014940. doi:10.1002/ajh.70339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。